TARS1

Across TCGA pan-cancer cohorts, TARS1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TARS1 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TARS1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TARS1 expression acts as an unfavorable survival marker.

LUAD, CCRCC, and PDAC are the cancer types where TARS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.490	0.928	<.001	34	view →
CCRCC	OS	Median	II,III,IV	0.339	1.000	.003	33	view →
PDAC	DFS	Tertile	III,IV	0.203	0.490	.004	26	view →
GBM	DFS	Tertile	All	0.230	0.410	.004	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TARS1–LUAD (OS)

Open the LUAD breakdown →